| A | B | C | D | E | F | |
|---|---|---|---|---|---|---|
1 | Trial Site Id | Subject Id | Arm | Randomization Date | Exists | |
2 | 1001 | 10011001 | SCREEN FAILURE | Present | ||
3 | 1001 | 10011002 | NOT ASSIGNED | Present | ||
4 | 1001 | 10011003 | SCREEN FAILURE | Present | ||
5 | 1001 | 10011004 | BNT162b1 Phase 1 (10 mcg) | 2020-05-04 | Present | |
6 | 1001 | 10011005 | Placebo | 2020-05-06 | Present | |
7 | 1001 | 10011006 | BNT162b1 Phase 1 (10 mcg) | 2020-05-06 | Present | |
8 | 1001 | 10011007 | BNT162b1 Phase 1 (10 mcg) | 2020-05-06 | Present | |
9 | 1001 | 10011008 | BNT162b1 Phase 1 (10 mcg) | 2020-05-06 | Present | |
10 | 1001 | 10011009 | BNT162b1 Phase 1 (10 mcg) | 2020-05-06 | Present | |
11 | 1001 | 10011010 | SCREEN FAILURE | Present | ||
12 | 1001 | 10011011 | BNT162b1 Phase 1 (30 mcg) | 2020-05-11 | Present | |
13 | 1001 | 10011012 | BNT162b1 Phase 1 (30 mcg) | 2020-05-13 | Present | |
14 | 1001 | 10011013 | Placebo | 2020-05-18 | Present | |
15 | 1001 | 10011014 | NOT ASSIGNED | Present | ||
16 | 1001 | 10011015 | BNT162b1 Phase 1 (30 mcg) | 2020-05-11 | Present | |
17 | 1001 | 10011016 | SCREEN FAILURE | Present | ||
18 | 1001 | 10011017 | BNT162b1 Phase 1 (30 mcg) | 2020-05-13 | Present | |
19 | 1001 | 10011018 | NOT ASSIGNED | Present | ||
20 | 1001 | 10011019 | BNT162b1 Phase 1 (30 mcg) | 2020-05-13 | Present | |
21 | 1001 | 10011020 | BNT162b1 Phase 1 (30 mcg) | 2020-05-13 | Present | |
22 | 1001 | 10011021 | Placebo | 2020-05-20 | Present | |
23 | 1001 | 10011022 | SCREEN FAILURE | Present | ||
24 | 1001 | 10011023 | SCREEN FAILURE | Present | ||
25 | 1001 | 10011024 | BNT162b1 Phase 1 (30 mcg) | 2020-05-13 | Present | |
26 | 1001 | 10011025 | SCREEN FAILURE | Present | ||
27 | 1001 | 10011026 | BNT162b1 Phase 1 (100/10 mcg) | 2020-05-18 | Present | |
28 | 1001 | 10011027 | NOT ASSIGNED | Present | ||
29 | 1001 | 10011028 | BNT162b1 Phase 1 (100/10 mcg) | 2020-05-20 | Present | |
30 | 1001 | 10011029 | SCREEN FAILURE | Present | ||
31 | 1001 | 10011030 | BNT162b1 Phase 1 (100/10 mcg) | 2020-05-20 | Present | |
32 | 1001 | 10011031 | NOT ASSIGNED | Present | ||
33 | 1001 | 10011032 | BNT162b1 Phase 1 (100/10 mcg) | 2020-05-20 | Present | |
34 | 1001 | 10011033 | NOT ASSIGNED | Present | ||
35 | 1001 | 10011034 | BNT162b1 Phase 1 (100/10 mcg) | 2020-05-20 | Present | |
36 | 1001 | 10011035 | SCREEN FAILURE | Present | ||
37 | 1001 | 10011036 | SCREEN FAILURE | Present | ||
38 | 1001 | 10011037 | BNT162b1 Phase 1 (10 mcg) | 2020-06-11 | Present | |
39 | 1001 | 10011038 | SCREEN FAILURE | Present | ||
40 | 1001 | 10011039 | BNT162b1 Phase 1 (10 mcg) | 2020-06-09 | Present | |
41 | 1001 | 10011040 | BNT162b1 Phase 1 (10 mcg) | 2020-06-11 | Present | |
42 | 1001 | 10011041 | BNT162b1 Phase 1 (10 mcg) | 2020-06-11 | Present | |
43 | 1001 | 10011042 | Placebo | 2020-06-11 | Present | |
44 | 1001 | 10011043 | BNT162b1 Phase 1 (20 mcg) | 2020-06-15 | Present | |
45 | 1001 | 10011044 | BNT162b1 Phase 1 (10 mcg) | 2020-06-09 | Present | |
46 | 1001 | 10011045 | BNT162b1 Phase 1 (10 mcg) | 2020-06-11 | Present | |
47 | 1001 | 10011046 | BNT162b1 Phase 1 (30 mcg) | 2020-06-18 | Present | |
48 | 1001 | 10011047 | SCREEN FAILURE | Present | ||
49 | 1001 | 10011048 | BNT162b1 Phase 1 (30 mcg) | 2020-06-16 | Present | |
50 | 1001 | 10011049 | BNT162b1 Phase 1 (20 mcg) | 2020-06-15 | Present | |
51 | 1001 | 10011050 | BNT162b1 Phase 1 (20 mcg) | 2020-06-17 | Present | |
52 | 1001 | 10011051 | SCREEN FAILURE | Present | ||
53 | 1001 | 10011052 | BNT162b1 Phase 1 (20 mcg) | 2020-06-17 | Present | |
54 | 1001 | 10011053 | Placebo | 2020-06-16 | Present | |
55 | 1001 | 10011054 | SCREEN FAILURE | Present | ||
56 | 1001 | 10011055 | BNT162b1 Phase 1 (20 mcg) | 2020-06-17 | Present | |
57 | 1001 | 10011056 | SCREEN FAILURE | Present | ||
58 | 1001 | 10011057 | Placebo | 2020-06-17 | Present | |
59 | 1001 | 10011058 | BNT162b1 Phase 1 (30 mcg) | 2020-06-18 | Present | |
60 | 1001 | 10011059 | BNT162b1 Phase 1 (20 mcg) | 2020-06-17 | Present | |
61 | 1001 | 10011060 | SCREEN FAILURE | Present | ||
62 | 1001 | 10011061 | BNT162b1 Phase 1 (30 mcg) | 2020-06-18 | Present | |
63 | 1001 | 10011062 | SCREEN FAILURE | Present | ||
64 | 1001 | 10011063 | BNT162b1 Phase 1 (30 mcg) | 2020-06-18 | Present | |
65 | 1001 | 10011064 | Placebo | 2020-06-18 | Present | |
66 | 1001 | 10011065 | SCREEN FAILURE | Present | ||
67 | 1001 | 10011066 | Placebo | 2020-06-29 | Present | |
68 | 1001 | 10011067 | BNT162b1 Phase 1 (20 mcg) | 2020-07-01 | Present | |
69 | 1001 | 10011068 | BNT162b1 Phase 1 (20 mcg) | 2020-06-29 | Present | |
70 | 1001 | 10011069 | Placebo | 2020-07-01 | Present | |
71 | 1001 | 10011070 | BNT162b1 Phase 1 (20 mcg) | 2020-07-01 | Present | |
72 | 1001 | 10011071 | BNT162b1 Phase 1 (20 mcg) | 2020-07-01 | Present | |
73 | 1001 | 10011072 | SCREEN FAILURE | Present | ||
74 | 1001 | 10011073 | SCREEN FAILURE | Present | ||
75 | 1001 | 10011074 | SCREEN FAILURE | Present | ||
76 | 1001 | 10011075 | SCREEN FAILURE | Present | ||
77 | 1001 | 10011076 | BNT162b1 Phase 1 (20 mcg) | 2020-07-01 | Present | |
78 | 1001 | 10011077 | NOT ASSIGNED | Present | ||
79 | 1001 | 10011078 | NOT ASSIGNED | Present | ||
80 | 1001 | 10011079 | SCREEN FAILURE | Present | ||
81 | 1001 | 10011080 | SCREEN FAILURE | Present | ||
82 | 1001 | 10011081 | Placebo | 2020-07-28 | Present | |
83 | 1001 | 10011082 | BNT162b2 Phase 2/3 (30 mcg) | 2020-08-03 | Present | |
84 | 1001 | 10011083 | BNT162b2 Phase 2/3 (30 mcg) | 2020-07-31 | Present | |
85 | 1001 | 10011084 | BNT162b2 Phase 2/3 (30 mcg) | 2020-07-28 | Present | |
86 | 1001 | 10011085 | BNT162b2 Phase 2/3 (30 mcg) | 2020-07-28 | Present | |
87 | 1001 | 10011086 | Placebo | 2020-07-28 | Present | |
88 | 1001 | 10011087 | BNT162b2 Phase 2/3 (30 mcg) | 2020-07-28 | Present | |
89 | 1001 | 10011088 | BNT162b2 Phase 2/3 (30 mcg) | 2020-07-28 | Present | |
90 | 1001 | 10011089 | BNT162b2 Phase 2/3 (30 mcg) | 2020-07-28 | Present | |
91 | 1001 | 10011090 | BNT162b2 Phase 2/3 (30 mcg) | 2020-07-29 | Present | |
92 | 1001 | 10011091 | BNT162b2 Phase 2/3 (30 mcg) | 2020-07-29 | Present | |
93 | 1001 | 10011092 | Placebo | 2020-07-29 | Present | |
94 | 1001 | 10011093 | BNT162b2 Phase 2/3 (30 mcg) | 2020-07-29 | Present | |
95 | 1001 | 10011094 | Placebo | 2020-07-29 | Present | |
96 | 1001 | 10011095 | BNT162b2 Phase 2/3 (30 mcg) | 2020-07-29 | Present | |
97 | 1001 | 10011096 | Placebo | 2020-07-29 | Present | |
98 | 1001 | 10011097 | BNT162b2 Phase 2/3 (30 mcg) | 2020-07-30 | Present | |
99 | 1001 | 10011098 | BNT162b2 Phase 2/3 (30 mcg) | 2020-07-30 | Present | |
100 | 1001 | 10011099 | Placebo | 2020-07-30 | Present |